Anti-Mouse/Human CXCL12 Antibody (K15C)
Based on 1 Customer Validation
Anti-Mouse/Human CXCL12 Antibody (K15C) is an antibody targeting SDF-1/CXCL12. Anti-Mouse/Human CXCL12 Antibody (K15C) blocks the biological activity of SDF-1 secreted by cancer-associated fibroblasts. Anti-Mouse/Human CXCL12 Antibody (K15C) inhibits tumor growth, reduces tumor microvessel density, and decreases the proportion of Sca1+CD31+ endothelial progenitor cells in tumors. Anti-Mouse/Human CXCL12 Antibody (K15C) can be used for research on aggressive human breast cancer. The recommended isotype control is Mouse IgG2a kappa, Isotype Control (HY-P99978).
For research use only. We do not sell to patients.
- Purity : 99.57%
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Mouse IgG2a kappa
Recommend Isotype Controls
Species Reactivity
Mouse/Human
IC50 & Target
[1]|
CXCL12 |
In Vitro
Anti-Mouse/Human CXCL12 Antibody (K15C) (10-20 μg/mL; 18 h) dose-dependently inhibits the enhanced in vitro chemotaxis of mouse Sca1+CD31+ endothelial progenitor cells (EPCs) toward human CAF1 cells, a process mediated by SDF-1/CXCL12 secreted by prostate cancer-associated fibroblasts (CAFs)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Immunodeficient nude mice[1]
-
Dosage:32 µg/mouse
-
Administration:i.p.; twice weekly; 68 days (starting one day prior to tumor cell injection)
-
Result:Greatly attenuated tumor growth, reduced tumor volume, and decreased tumor weight compared to CAF-containing tumors treated with control IgG.
Reduced microvascular density by 53% in CAF-containing tumors compared to control IgG treatment.
Decreased the proportion of Sca1+CD31+ endothelial progenitor cells (EPCs) within tumor masses by 36% in CAF-containing tumors compared to control IgG treatment.
Did not significantly affect tumor growth, angiogenesis, or EPC recruitment in tumors formed with control counterpart fibroblasts.
Gene ID
Accession
P40224
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vivo neutralization of CXCL12/SDF-1; in vitro neutralization of CXCL12/SDF-1; in vitro functional
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse/Human CXCL12 Antibody (K15C) Related Classifications
HY-P991795 Related Classifications
Powered by Bioz